pharma is the sole category represented across all 1 tracked stories. Abbott Laboratories is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Stephen Hemsley appears in 1 tracked Biotech story from July 25, 2026. The tracked stories average 1 original source each.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Stephen Hemsley
pharma is the sole category represented across all 1 tracked stories. Abbott Laboratories is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Stephen Hemsley appears in 1 tracked Biotech story from July 25, 2026. The tracked stories average 1 original source each.
Stories tracked
1
Sources per story
1
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 15 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Stephen Hemsley. Shared-story counts are live from our verified record — not editorial picks.
Abbott Laboratories reported Q2 revenue of $12.59 billion (+13% YoY), beating estimates and raising its full-year EPS guidance. Analysts hiked price targets in response, with BTIG going to $134, reflecting confidence in its diversified healthcare portfolio and pipeline. UnitedHealth also delivered a massive EPS beat, but Abbott’s medtech and diagnostics momentum carries particular relevance for the biopharma sector.
